Roppolo L P, Fitzgerald R, Dillow J, Ziegler T, Rice M, Maisel A
Department of Medicine, Veteran's Affairs Medical Center and University of California, San Diego, USA.
J Am Coll Cardiol. 1999 Aug;34(2):448-54. doi: 10.1016/s0735-1097(99)00207-7.
The purpose of this study was to prospectively evaluate the usefulness of the cardiac troponins as predictors of subsequent cardiac events in patients with chronic renal failure undergoing dialysis.
Cardiac troponin T (cTnT) and I (cTnI) are cardiac markers that are specific for cardiac muscle. They are also excellent prognostic indicators for patients presenting with chest pain. Although cardiac disease is the leading cause of death in dialysis patients, standard methods to diagnose acute coronary syndromes in patients with renal failure are often misleading.
A six-month prospective study was done in a university-affiliated Veterans Hospital's dialysis clinic. Forty-nine patients undergoing chronic dialysis with no complaints of chest pain were followed for cardiac events occurring in the six months after cardiac troponin measurements. These included unstable angina, acute myocardial infarction and cardiac death. An additional 83 patients with renal failure but who were not undergoing dialysis were also examined.
Within six months all three dialysis patients with elevated cTnI at entry into the study suffered an adverse complication (specificity and positive predictive value = 100%). Twenty-five patients had cTnT elevated at >0.10 ng/ml (53%). Patients with diabetes were more likely to have elevated troponin T levels (64% vs. 25%, p = 0.01). All six patients developing cardiac events within three months had elevations of cTnT >0.1 ng/ml (sensitivity = 100%). Whereas the specificity of cTnT was only 56% for a near-term cardiac event, the negative predictive value of cTnT using a cutoff of < or = 0.1 ng/ml was 100%. On restratifying patients using a cutoff value of cTnT of >0.2 ng/ml, only nine of 49 dialysis patients (18%) had elevated levels. In patients with renal failure not undergoing dialysis, only three of 83 (4%) had elevated troponin I or T. None of these patients suffered a cardiac event in the next six months.
This prospective pilot study clearly delineates the troponins as important prognosticators in asymptomatic otherwise "stable" patients on chronic dialysis, especially those with concomitant diabetes mellitus. It also appears that troponins are more likely to be elevated in dialysis patients than other patients with renal failure not on dialysis. The above suggests that the combination of cTnI and cTnT might be very effective in elucidating cardiac risks of patients with renal failure undergoing chronic dialysis.
本研究旨在前瞻性评估心肌肌钙蛋白作为接受透析的慢性肾衰竭患者后续心脏事件预测指标的有效性。
心肌肌钙蛋白T(cTnT)和I(cTnI)是心肌特异性的心脏标志物。它们也是胸痛患者的优秀预后指标。尽管心脏疾病是透析患者的主要死因,但诊断肾衰竭患者急性冠状动脉综合征的标准方法常常具有误导性。
在一所大学附属医院的退伍军人医院透析诊所进行了一项为期六个月的前瞻性研究。对49例无胸痛主诉的慢性透析患者进行随访,观察心肌肌钙蛋白测量后六个月内发生的心脏事件。这些事件包括不稳定型心绞痛、急性心肌梗死和心源性死亡。另外还检查了83例肾衰竭但未接受透析的患者。
在研究开始时,cTnI升高的所有3例透析患者在六个月内均发生了不良并发症(特异性和阳性预测值 = 100%)。25例患者的cTnT升高至>0.10 ng/ml(53%)。糖尿病患者的肌钙蛋白T水平更有可能升高(64%对25%,p = 0.01)。在三个月内发生心脏事件的所有6例患者的cTnT均升高至>0.1 ng/ml(敏感性 = 100%)。虽然cTnT对近期心脏事件的特异性仅为56%,但使用≤0.1 ng/ml的临界值时,cTnT的阴性预测值为100%。使用cTnT>0.2 ng/ml的临界值对患者重新分层时,49例透析患者中只有9例(18%)水平升高。在未接受透析的肾衰竭患者中,83例中只有3例(4%)肌钙蛋白I或T升高。这些患者在接下来的六个月内均未发生心脏事件。
这项前瞻性初步研究明确表明,肌钙蛋白是慢性透析无症状“稳定”患者的重要预后指标,尤其是合并糖尿病的患者。似乎透析患者的肌钙蛋白比未透析的其他肾衰竭患者更有可能升高。以上结果表明,cTnI和cTnT联合使用可能对阐明接受慢性透析的肾衰竭患者的心脏风险非常有效。